Carcinotech dominates the summer awards season

Carcinotech dominates the summer awards season

Carcinotech dominates the summer awards season

Over the past six years, Carcinotech has focused on the development, optimization and commercialization of our innovative drug development platform. During this time, we have invested significantly in state-of-the-art imaging and bioprinting technology and recruited highly specialized personnel from leading academic and industry institutes. This focus has led to unparalleled expertise in oncology, bioengineering and assay development, as well as multiple international patents pending for our technology.

The recognition we received this summer is testament to our tireless hard work and we are honored by the awards, which recognize the significant progress we are making.

Here is a summary of the recent awards we have proudly received:

Best EIS Investee of the Year, EISA 2024 – Carcinotech

We are delighted to have been named Best EIS Investment Company of the Year at the Enterprise Investment Scheme Awards 2024. The Enterprise Investment Scheme (EIS) facilitates the smooth flow of venture capital from individuals to early stage companies, offering them vital support to enable growth. These awards recognize the outstanding achievements of the program's participants and we are grateful for the recognition and unwavering support of the EIS. This award also underlines our commitment to innovation, growth and providing excellent service to our customers.

Entrepreneur of the Year, EISA 2024 – Ishani Malhotra (CEO & Founder)

Congratulations to our CEO, Ishani Malhotra, on being named Entrepreneur of the Year at the EISA Awards 2024. This award recognizes Ishani's decisive leadership and commitment to making Carcinotech's mission a reality: to be at the forefront of cancer drug testing and to provide personalized drug testing to improve the treatment and survival rates of cancer patients worldwide.

Under Ishani's leadership, Carcinotech has partnered with leading pharmaceutical and biotech companies, significantly increasing our commercial growth and expanding our market reach.

Additionally, Ishani is quickly becoming a respected leader in the field, speaking at prestigious events such as the BIO International Convention 2024, where she advocates for more ethical and relevant models for drug discovery and development to a global audience.

Cancer Research UK #ResearchIsBeautiful June Campaign Winner - Michaela MacDonald (Imaging Scientist)

Carcinotech imaging scientist Michaela MacDonald was selected as the winner of Cancer Research UK's (CRUK) online Research Is Beautiful campaign in June. CRUK launched this campaign to celebrate the beauty and advances of imaging in cancer research. Our Winner The image shows one of our 3D bioprinted live tumors derived from donor glioblastoma tissue, highlighting the complexity of the tumor microenvironment (TME). The TME is critical in cancer research because it accurately models tumor complexity, drug resistance mechanisms, and immune interactions, leading to more predictive preclinical models and effective, personalized cancer therapies. We are proud to have been recognized by CRUK, demonstrating how the physiological similarity of our bioengineered tumors makes them invaluable tools for cancer drug discovery. Keep it up, Michaela!

Hard Tech Investment of the Year UKBAA 2024 – Carcinotech

Carcinotech is delighted to have won the Hard Tech Investment of the Year award at the UK Business Angels Association (UKBAA) Angel Investment Awards 2024. Sponsored by Mathys & Squire, the award recognizes the founders and early-stage investors whose disruptive innovations in research-intensive and capital-intensive sectors such as healthcare and life sciences, engineering and manufacturing are driving the economy of the future.

The awards, held on July 3, were a celebration of the success and determination of the angel and early-stage investment community. Thank you, UKBAA, for recognizing the groundbreaking work we are doing to bring effective cancer therapeutics to market faster.

We would also like to congratulate our CEO, Ishani Malhotra, who was named a finalist for the High Growth Women Founder of the Year award in recognition of her commitment to leading Carcinotech to sustainable growth.

Thanks

We extend our heartfelt thanks to our great employees, valued customers, industry partners and supportive investors. The recognition we have received is humbling and gives new strength to our pursuit of progress and innovation. Stay tuned for more exciting updates and milestones as we move forward on our journey!

Would you like to join our exciting, award-winning company? Check out our open positions on our LinkedIn page.

Sources: